Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2013 12:32 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Issues Letter to Shareholders

NEW YORK, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
February 07, 2013 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Initiates in vivo Proof of Concept Studies in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody

NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
January 02, 2013 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences CEO Daniel Chain Provides Conference Highlights of Alzheimer's Drug Development Summit in Neurotech Insights Magazine

NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, provided conference highlights from the December 11-12...
December 06, 2012 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences CEO Daniel Chain to Discuss Vaccine Program at Alzheimer's Drug Development Summit

NEW YORK, Dec. 6, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will discuss Intellect's vaccine program at the Alzheimer's Drug...
November 28, 2012 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Announces New Findings Supporting its Patented ANTISENILIN Platform Technology for the Treatment of Alzheimer's Disease

NEW YORK, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
November 06, 2012 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Announces New Findings Supporting Its Tau Oligomer Selective TOC-1 Monoclonal Antibody for the Treatment of Alzheimer's Disease

NEW YORK, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
October 16, 2012 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Issues Letter to Shareholders

NEW YORK, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
October 15, 2012 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences Files Lawsuit Against Pharmaceutical Licensee for Non Payment of $2 Million Milestone

NEW YORK, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
October 03, 2012 09:35 ET | Source: Intellect Neurosciences, Inc.

Intellect Neurosciences and iNovacia Enter Research Service Agreement to Evaluate Lead Compounds for CONJUMAB-A Program

NEW YORK and STOCKHOLM, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying...
September 27, 2012 09:35 ET | Source: Intellect Neurosciences, Inc.

Lonza and Intellect Neurosciences Announces Intellect's Intention to Award Production of Its Antibody Drug Conjugate, CONJUMAB-A to Lonza

NEW YORK and BASEL, Switzerland, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Lonza announced today that Intellect Neurosciences, Inc. (OTCBB:ILNS) awarded the future development and manufacture of the antibody...